Bioatla Inc (BCAB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.90 (-20.83%), Market cap $0.01B, 52-week low–high $0.13 ~ $5.84.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA318
Financial statements, price targets, institutional (13F) holdings and related news for Bioatla Inc are updated in real time on BlackAll Trade.
Bioatla Inc trades at $1.90 (-20.83%). Real-time quotes and charts are available on BlackAll Trade.
Bioatla Inc has a market cap of about $0.01B.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidat